Navigation Links
Quest Diagnostics Brings Genetic Testing for Plavix(R) Response to Coronary Stent Patients at Scripps Health
Date:10/7/2009

MADISON, N.J., Oct. 7 /PRNewswire/ -- DNA testing for gene variants that can increase the risk of major coronary events in certain patients taking the anti-clotting drug Plavix® (clopidogrel bisulfate) is now being performed by Quest Diagnostics (NYSE: DGX) for Scripps Health patients electing to undergo coronary stent procedures. Scripps Health is believed to be the first health system in the U.S. to deploy this genetic testing service for coronary stent patients as part of patient treatment. Scripps physicians will initially offer the genetic tests to elective stent patients before they undergo their procedures at Scripps Green Hospital in San Diego.

The Quest Diagnostics test is designed to help improve outcomes for stent recipients by enabling Scripps Health cardiologists to personalize therapy based on diagnostic insights into a patient's genetic makeup.

"Our collaboration with Quest Diagnostics represents a landmark program in individualized medicine, based on considerable new data and new choices for one of the most commonly prescribed medications and medical procedures in the world," said Dr. Eric Topol, chief academic officer of Scripps Health. "This program demonstrates Scripps Health's commitment to being at the forefront of individualized cardiovascular medicine."

Most of the one million patients who undergo stent procedures in the U.S. each year receive Plavix to help prevent blood clots that can cause heart attacks and strokes. Yet, large-scale, peer-reviewed studies demonstrate that patients with one or more mutated alleles (variants) of the Cytochrome (CYP) 2C19 gene are unable to respond properly to Plavix, increasing their risk of death, heart attack or stroke compared to people with normal alleles. About one third of people of Caucasian descent, and 40 percent or more of people of African and Asian descent, possess common polymorphisms in the CYP2C19 gene.

The Quest Diagnostics test is believed to be the first provided by a national laboratory to combine testing for the normal version of the CYP2C19 gene and four mutations that appear in the genetics of 90 percent of Caucasians and 99 percent of Asians who are poor metabolizers of clopidogrel. Specifically, the test, which employs polymerase chain reaction (PCR), indicates if a patient will respond normally to clopidrogel (has the wild type, or normal, CYP2C19*1 allele) or not normally because of the presence of one or more of four mutated alleles (CYP2C19*2, CYP2C19*3, CYP2C19*4 or CYP2C19*5).

The saliva-based test allows specimens to be collected at a physician's office or by the patient in his or her home. It is the first saliva-based test for cardiovascular disease developed by Quest Diagnostics. The company expects to offer the saliva- and blood-based versions of the test nationally to its other clients this month.

Patients who test positive for the mutated alleles may receive alternative treatments based on a variety of factors. These treatments may include increased monitoring, an increased dosage of clopidogrel or the use of alternative therapies, including treatment with Effient® (prasugrel), a blood thinner approved by the FDA in July 2009.

"Our collaboration with Scripps Health reflects our commitment to developing diagnostics based on quality research and superlative medical expertise," said Jon R. Cohen, M.D., a former vascular surgeon who is now senior vice president and chief medical officer for Quest Diagnostics. "We look forward to continuing to work with Scripps to design forward-thinking diagnostics and medical practices that, like CYP testing, can have a significant favorable impact on patient outcomes."

About Scripps Health

Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps Health is a $2 billion nonprofit community health system based in San Diego, Calif. Scripps treats a half-million patients annually through the dedication of 2,600 affiliated physicians and 12,700 employees among its five acute-care hospital campuses, home health care services, and an ambulatory care network of physician offices and 19 outpatient centers and clinics. Recognized as a leader in the prevention, diagnosis, and treatment of disease, Scripps is also at the forefront of clinical research and graduate medical education. More information can be found at www.scripps.org.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

Quest, Quest Diagnostics, the associated logo, Nichols Institute and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics.

Plavix, Effient, and all other third party marks -- ®' and (TM)' -- are the property of their respective owners. © 2000-2009 Quest Diagnostics Incorporated. All rights reserved.

    Quest Diagnostics Contacts:
    Wendy Bost (Media): 973-520-2800
    Kathleen Valentine (Investors): 973-520-2900

SOURCE Quest Diagnostics


'/>"/>
SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemedica Requests Pre-IND Meeting With FDA
2. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
3. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
4. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
5. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
6. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
7. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
8. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
9. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
10. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
11. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):